Abstract
Introduction

▼
Smoking is the single biggest preventable cause of death in contemporary societies. Unfortunately, available treatments against tobacco dependence are only eff ective for a minority of smokers. Current guidelines recommend nicotine patches as the fi rst line of treatment, yet ~70-80 % of smokers under this treatment relapse in the long-term [ 1 ] . Although bupropion produces higher quitting rates than nicotine substitutive treatment (NST), the majority of smokers do not remain abstinent after the treatment [ 2 ] . Varenicline has been tested in several double-blind clinical trials involving smokers, and the results indicate a signifi cant eff ect on smoking cessation rates. However, further trials are needed to determine the superiority of varenicline over the other fi rst-line treatments available [ 3 ] . Cigarette consumption and smoking cessation are infl uenced in part by genes [ 4 , 5 ] . The psychoactive properties of nicotine are closely related to its brain concentration (Benowitz NL 1989) . Approximately 60 % of the variability in nicotine metabolism is heritable, and reduced-activity and inactive variants of the CYP2A6 gene associated with slower nicotine clearance have been well characterized [ 6 , 7 ] . In spite of polymorphisms in genes encoding nicotine-metabolizing enzymes, personality traits have also been implicated in the aetiology of smoking [ 5 , 8 ] . Depressive disorder has been associated with cigarette consumption and smoking cessation failure in several cross-sectional and longitudinal studies [ 9 , 10 ] . Anxious persons tend to smoke more and have more diffi culty quitting smoking [ 11 ] . Nicotine elevates the secretion of serotonin in the brain [ 12 ] . Therefore, variations in the serotonergic system, including serotonin-producing cells, serotonin transporters, and serotonin receptors, may infl uence some aspects of smoking behaviour. Moreover, nicotine withdrawal decreases serotonin levels and a selective serotonin reuptake inhibitor antagonizes the response to nicotine [ 13 ] . Controversy exists on the specifi c genetic variants that have functional consequences on such phenotypes, yet a strong rationale exists for polymorphisms in genes encoding nicotinemetabolizing enzymes in the liver [cytochrome P450 2A6 ( CYP2A6 ) and B6 ( CYP2B6 )] [ 8 , 14 ] . Other plausible candidate polymorphisms are in genes involved in serotoninergic pathways related to nicotine reward, mood and dependence, such as serotoninergic transporter [ 5- HTT , also termed solute carrier family 6, member 4 ( SLC6A4 )] and receptor ( HTR2A ) [ 15 -17 ] . Our purpose was to assess the association of the eff ectiveness of nicotine or bupropion treatment against tobacco dependence, with 6 candidate genetic variants:
Patients and Methods
▼
76 heavy smokers [all of Caucasian (Spanish) descent for ≥ 3 generations, 54 women, mean ± SD age 45 ± 9 years] were recruited in a randomized manner from the Hospital Gregorio Marañón (Spain). Approximately 90 people were screened in the smoking cessation program between 2007 and 2010 but only 76 individuals were included in the study. Patients were motivated to stop smoking and went there to try to stop smoking on their own without any kind of advertisement or recruitment method. Inclusion criteria were: (i) to be enrolled in a 'standard' (12-week duration) smoking cessation program with nicotine substitutive treatment (NST) or bupropion following medical criteria, (ii) smoking history > 10 cigarettes/day and > 10 packs/year, and (iii) > 3 scores in the Fagerstrom test for nicotine dependence (FTND).
It was an open label trial and the doses of bupropion SR provided were (150 mg once/day for days 1-6, followed by 150 mg twice/ day for days 7-84), 12 weeks. For NRT the doses were: 1) for smokers ≥ 20 cigarettes/day, Nicotinell TTS 30 (4 weeks), Nicotinell TTS 20 (4 weeks) and Nicotinell TTS 10 (4 weeks), 2) for smokers < 20 cigarettes/day, Nicotinell TTS 20 (4 weeks), Nicotinell TTS 20 (4 weeks) and Nicotinell TTS 10 (4 weeks). Approval was obtained from the local Ethics Committee ( Hospital Gregorio Marañón ) and all patients provided written informed consent. The study was in accordance with the Helsinki Declaration. Treatment eff ectiveness was defi ned as prolonged abstinence for 12 months post-treatment and the abstinence rate was measured at 3, 6, 9 and 12 months during the follow-up visits.
We selected the aforementioned genetic polymorphisms according their prevalence in the Spanish population and phenotypic eff ects. Genotyping was performed from blood samples using an allele-specifi c polymerase chain reaction as detailed elsewhere [ 18 ] . We compared smoking phenotypes between the 2 treatment groups (nicotine or bupropion) with the unpaired Student's t -test. We used the χ 2 test to assess deviations of genotype distributions from the Hardy-Weinberg equilibrium (HWE). We also used a logistic regression to analyse the association between treatment outcome and genotypes or genotype combinations (see below). We combined CYP2A6 genotypes in 3 diff erent groups based on expected enzymatic activity levels, i. e.: 'slow' (50 % activity), 'medium' (80-100 % activity) and 'fast metabolizers' ( > 100 % activity) [ 19 ] . All statistical analyses were corrected for multiple comparisons using the Bonferroni method, in which the threshold P value is obtained by dividing 0.05 by the number of tests. All analyses were performed with the PASW/SPSS Statistics 18.0 (SPSS Inc, Chicago, IL) program.
Results
▼
The study included 76 patients demanding smoking cessation treatment between May 2006 and July 2009. 70 of the 76 people completed the followed up period. All participants were at the preparation or contemplation stage in the process of quitting smoking. The number of subjects in the NST and bupropion group was n = 36 (25 women) and n = 34 (29 women), respectively. Main smoking phenotypes did not diff er between the 2 treatment groups, i. e., mean ± SD of 23.4 ± 10.2 and 23.6 ± 9.6 cigarettes/day for NST and bupropion, respectively ( P = 0.943), smoking history of 29.6 ± 5.5 and 24.7 ± 9.0 years ( P = 0.080), and FTND score of 6.8 ± 2.0 and 5.8 ± 2.1 ( P = 0.051). Likewise, treatment eff ectiveness did not diff er between the NST and bupropion groups, being successful in 39 % and 38 % of subjects ( P = 0.575).
Genotype success was 100 %. Genotype frequencies are shown in • ▶ 
Discussion
▼
Although preliminary, the results of our study provide evidence that several genetic variations, especially in CYP2A6 gene (and thus leading to diff erent phenotypes in terms of rate of nicotine metabolization) may infl uence the success of smoking cessation treatment. It is possible that anxiety (altered serotonin activity), a common symptom of nicotine withdrawal, may be a critical factor in the maintenance of smoking and decrease smoking cessation success. We believe that our fi ndings are of clinical relevance because up to date there is no clear consensus or criteria on when to select nicotine or bupropion for inducing tobacco cessation. Yet several genetic factors identifi ed here have a strong infl uence on treatment eff ectiveness, at least in the case of nicotine, and could be used to predict treatment eff ectiveness. Combining variants resulted in a pronounced increase of cessation rates. In slow metabolizers (based on CYP2A6 genotype) treatment is likely to be clearly more successful with nicotine than with bupropion, and thus the former could be the selected treatment. This is consistent with the fi nding that nicotine slow-metabolizers have higher plasma nicotine levels compared with normal/fast metabolizers [ 22 ] . Thus, the higher treatment-related plasma nicotine levels among slow metabolizers compared with normal metabolizers may contribute to greater quitting success during nicotine therapy [ 24 ] . NTS success was also higher in those participants carrying the 'high-activity' L-allele of the 5HTT LPR gene or the HTR2A 1438GG genotype. Nicotine increases brain serotonin secretion (with serotonergic tone therefore playing a role in nicotine eff ects) while nicotine withdrawal has the opposite eff ects [ 25 ] . Thus, genotypes associated with reduced synaptic serotonin activity (e. g., decreased serotonin synthesis, decreased serotonin receptor activity, or increased serotonin transporter activity) might be associated with higher success rates of nicotine treatment for smoking cessation, given the need to self-medicate nicotine withdrawal [ 11 ] . To the best of our knowledge, there are no previous studies on the HTR2A -1438A > G polymorphism and smoking cessation in spite of the fact that this polymorphism has been associated with a better response to antidepressant treatment [ 26 ] . Approximately ~40 % of our cohort had the 'favourable' genotype combination (for CYP2A6 , 5HTT LPR or HTR2A ). Such a genetic endowment is expected to result in considerably higher smoking cessation rates after 12 months (~63 %) than the actual value of 38 % reported for the nicotine group. As for bupropion treatment, only the CYP2A6 genotype provided a certain predictive value for treatment eff ectiveness. Thus, more research in genetic factors is needed to predict the success of other alternative treatments for nicotine cessation, e. g., antidepressants such as nortriptyline [ 21 ] . We believe this is the fi rst association study in a Spanish population in the fi eld of genetics and tobacco cessation performed with heavy smokers which takes into account the most important polymorphisms that are strong candidates to infl uence smoking behaviour, i. e., those involved in nicotine metabolization, as well as in the brain eff ects of nicotine. The results of our study are overall valid, as all the following criteria were met [ 27 ] : the smoking phenotypes and the study outcome were properly defi ned and accurately recorded by a researcher who was blind to the genetic information; we adjusted all statistical inferences for multiple comparisons (Bonferroni's criteria for the p values); and the results are overall consistent with previous research in the fi eld. A weakness of our study was the low sample size of the 2 treatment groups, yet we believe this can be partly overcome by the fact that both groups were homogeneous and well defi ned in terms of phenotype assessment. Keeping in mind the values of large-scale population nicotine dependence association studies, the limitation of their interpretation and also their usefulness in the clinical (and pharmacological) innovations are suggested. In accordance with this, studies with more sophisticated designs (including more appropriate phenotype measures, representative population) are required even with the risk of smaller sample size. In summary, we provided preliminary evidence supporting that genetic screening can be useful to predict success of nicotine treatment against smoking cessation and thus can contribute to reduce the mortality caused by smoking.
